Evidence map›Paper›PMID 35675040›Full record

ArticleHuman vaccines & immunotherapeutics2022

Assessment of mumps-containing vaccine effectiveness by dose during 2006 to 2020 in Quzhou, China.

Zhiying Yin, Tingcui Wen, Quanjun Fang, Canjie Zheng, Xiaoying Gong, Junji Li, Shuangqing Wang, Ziling Xiang

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhiying YinDepartment of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang Province, China.ORCID 0000-0002-7678-5989
Tingcui WenSchool of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China.
Quanjun FangDepartment of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang Province, China.
Canjie ZhengDepartment of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang Province, China.
Xiaoying GongDepartment of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang Province, China.
Junji LiDepartment of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang Province, China.
Shuangqing WangDepartment of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang Province, China.
Ziling XiangDepartment of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mumps cases were reported frequently when a routine dose measles-mumps-rubella(MMR) achieved high coverage in Quzhou. The supplementary immunization activities (SIA) using measles mumps (MM) was conducted to control mumps outbreaks. The effectiveness of one and two doses of mumps-containing vaccine (MuCV) was assessed using surveillance data in this study. Mumps cases and immunization information were retrieved from the National Notifiable Disease Reporting System (NNDRS) and the Zhejiang Provincial Immunization Information System (ZJIIS), respectively. Mumps cases of children born from 2006 to 2010 were included. Vaccine effectiveness by dose was calculated using the screening method. A total of 956 mumps cases were identified, of whom 754 (78.9%) had received one dose of MuCV; 108 (11.3%) had received two doses; 94 (9.8%) were unvaccinated. The coverage of one-dose MuCV in the 2006-2010 birth cohorts ranged from 91.6% to 98.9%. Except the 2009 birth cohort in which the coverage of two doses of MuCV was 55.1%, the others were less than 10%. Vaccine effectiveness (VE) of one dose ranged from 47.4% to 86.0%, while VE of two doses ranged from 64.0% to 92.4%. The VE of one and two doses of MuCV waned over time, but the VE of two doses was consistently higher than that of one dose in the same period. The vaccine schedule with two-dose MMR should be implemented among children in Quzhou. The optimal age for the second dose needs to be further evaluated.

Indexed as

MeaslesMumpsRubellaChildChinaHumansImmunization ScheduleInfantMeasles-Mumps-Rubella VaccineMumps VaccineVaccine EfficacyMeasles-Mumps-Rubella VaccineMumps VaccineMumpsmumps-containing vaccinevaccine effectiveness

Identifiers

PMID35675040
PMCPMC9621056

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.